source
- Lilly shares slide as Foundayo prescriptions lag expectations, while Novo's Wegovy gains momentumEli Lilly's stock fell nearly 5% after the latest weekly prescription count for its obesity drug Foundayo missed analysts' expectations. IQVIA data showed U.S. prescriptions for Foundayo reached 3…
- FDA approves Regeneron’s Otarmeni gene therapy for rare inherited hearing lossThe FDA has approved Otarmeni, a gene therapy from Regeneron, marking the first therapy cleared under the agency’s national priority voucher program and will be provided to eligible patients at no…